GDOC News and Press, Goldman Sachs Future Health Care Equity ETF From 08/10/22

Catalent has built up a solid track record of value creation over the past nearly decade long period. The company has seen excellent operating momentum, despite the pandemic being on its retreat. With shares lagging, valuations have become a lot more compelling, not to be confused...

SWAV's approval to distribute products in China to significantly boost revenue growth in the coming quarters. SWAV posted strong Q1 2022 results with a solid FY22 outlook. The company is overvalued at current price level despite taking into account the robust growth rate. I as...

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock’s expected coming price range limits. By comparing today’s balance of upside and downside price change p...

The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV. A tremendous earnings report...